Abstract
It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the “belly bath” as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dedrick RL et al (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11
Speyer JL, Myers CE (1980) The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies. Recent Results Cancer Res 74:264–269
Speyer JL et al (1980) Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40(3):567–572
Casper ES et al (1983) Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 67(3):235–238
Howell SB et al (1982) Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97(6):845–851
Howell SB et al (1987) Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5(10):1607–1612
Francis P et al (1995) Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 13(12):2961–2967
Markman M et al (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 10(9):1485–1491
Muggia FM et al (1996) Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy – a randomized phase II study by the Southwest Oncology Group. Gynecol Oncol 61(3):395–402
Alberts DS et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335(26):1950–1955
Alberts DS et al (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10(5):706–717
Ozols RF et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200
Markman M et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19(4):1001–1007
Rothenberg ML et al (2003) Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial. J Clin Oncol 21(7):1313–1319
Armstrong DK et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43
Hess LH, Chambers SK, Alberts DS (2008) Role of intraperitoneal chemotherapy for ovarian cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA (eds) Cancer principles and practice of oncology. Wolters Kluwer Health, Inc, New York
Wenzel LB et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25(4):437–443
Trimble EL, Christian MC (2006) Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 100(1):3–4
Trimble EL, Alvarez RD (2006) Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol 103(2 suppl 1):S18–S19
Hess LM et al (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 17(3):561–570
Jaaback K, Johnson N (2006) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (review). Cochrane Database Syst Rev 25; (1): CD 005340
Markman M et al (1992) Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol 10(9):1479–1484
Gore M et al (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 16(7):2426–2434
McGuire WP et al (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13(7):1589–1599
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Alberts, D.S., Clouser, M.C. (2010). Intraperitoneal Chemotherapy: Phase III Trials. In: Alberts, D., Clouser, M., Hess, L. (eds) Intraperitoneal Therapy for Ovarian Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12130-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-12130-2_4
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12129-6
Online ISBN: 978-3-642-12130-2
eBook Packages: MedicineMedicine (R0)